Co-Diagnostics Inc Registered Shs CODX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Co-Diagnostics, Inc. to Accompany Utah Governor and WTC Utah on Trade Mission to South Korea and Japan
-
Co-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test
-
Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C.
-
Co-Diagnostics, Inc. Reports Second Quarter 2024 Financial Results
-
Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago
-
Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast
-
Co-Diagnostics Shares Rise 21% After Submitting FDA Application For Covid-19 Test Platform
Trading Information
- Previous Close Price
- $1.23
- Day Range
- $1.15–1.29
- 52-Week Range
- $0.98–2.23
- Bid/Ask
- $1.15 / $1.29
- Market Cap
- $39.89 Mil
- Volume/Avg
- 64,918 / 245,908
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.06
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 0.82%
Company Profile
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 155
- Website
- https://www.codiagnostics.com
Comparables
Valuation
|
Metric
|
CODX
|
GRAL
|
VCYT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 76.43 |
Price/Book Value | 0.55 | 0.16 | 2.31 |
Price/Sales | 4.06 | 3.89 | 6.37 |
Price/Cash Flow | — | — | 37.72 |
Price/Earnings
CODX
GRAL
VCYT
Financial Strength
|
Metric
|
CODX
|
GRAL
|
VCYT
|
|---|---|---|---|
Quick Ratio | 8.56 | 11.09 | 3.96 |
Current Ratio | 9.09 | 11.55 | 4.44 |
Interest Coverage | — | — | −13,015.40 |
Quick Ratio
CODX
GRAL
VCYT
Profitability
|
Metric
|
CODX
|
GRAL
|
VCYT
|
|---|---|---|---|
Return on Assets (Normalized) | −32.00% | −11.72% | 9.55% |
Return on Equity (Normalized) | −35.24% | −13.53% | 10.25% |
Return on Invested Capital (Normalized) | −35.39% | −13.47% | 9.19% |
Return on Assets
CODX
GRAL
VCYT
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| Nfktjjxy | Vnsjq | $198.4 Bil | |||
| Stryker Corp
SYK
| Jpbxwjfczs | Lhszl | $137.7 Bil | |||
| Boston Scientific Corp
BSX
| Qfjcbdlml | Hggpc | $123.4 Bil | |||
| Medtronic PLC
MDT
| Rwcvdwbdg | Jdywhv | $115.5 Bil | |||
| Edwards Lifesciences Corp
EW
| Hrzljwgnsj | Bzcbcy | $39.8 Bil | |||
| Koninklijke Philips NV ADR
PHG
| Qsvsp | Nssmw | $30.6 Bil | |||
| DexCom Inc
DXCM
| Sgvmgvjtn | Xgql | $26.9 Bil | |||
| Steris PLC
STE
| Nmkgydlj | Ggwhkr | $23.9 Bil | |||
| Zimmer Biomet Holdings Inc
ZBH
| Tdhbgjct | Kntwc | $22.0 Bil | |||
| Insulet Corp
PODD
| Rsxqdfmvcb | Hgwqfq | $16.3 Bil |
United States